All In Biotech

Drug Trial Radar · NCT00574873

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN SUBJECTS WITH NEWLY DIAGNOSED CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA

Last checked: Nov 20, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 502 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

502

Actual

Start

Feb 5, 2008

Primary completion

Aug 31, 2010

Study completion May 27, 2015

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
First posted
Dec 17, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one year.

Conditions

  • Chronic Myeloid Leukemia

Interventions

  • BosutinibDrug

    500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.

  • imatinibDrug

    400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1Time frame: Year 1 (48 weeks)

Locations

165 sites in 29 countries. Site status is shown where the registry gives one.

  • Pacific Cancer Medical Center Inc

    Anaheim, California

  • Tower Cancer Research Foundation (TCRF)

    Beverly Hills, California

  • Robert A Moss, MD, FACP, Inc

    Fountain Valley, California

  • UCSD Medical Center-Thornton

    La Jolla, California

  • UCSD Moores Cancer Center

    La Jolla, California

  • UCSD Medical Center-Hillcrest

    San Diego, California

  • Stanford Hospital and Clinics Investigational Drug Services

    Stanford, California

  • Stanford Hospitals and Clinics

    Stanford, California

  • Stanford University Medical Center

    Stanford, California

  • Cancer Care Centers of Florida

    Hudson, Florida

  • Cancer Care Centers of Florida

    New Port Richey, Florida

  • Pasco Pinellas Cancer Center

    New Port Richey, Florida

  • Orlando Health, Inc.

    Orlando, Florida

  • Pasco Pinellas Cancer Center

    Tarpon Springs, Florida

  • Northside Hospital, Inc. - GCS/Annex

    Atlanta, Georgia

  • Indiana Blood and Marrow Transplantation Research Franciscan St. Francis Health Center Inc.

    Indianapolis, Indiana

  • Indiana Blood and Marrow Transplantation Research

    Indianapolis, Indiana

  • Siouxland Hematology-Oncology Associates, LLP

    Sioux City, Iowa

  • Cancer Center of Kansas

    Salinas, Kansas

  • Cancer Center of Kansas

    Wichita, Kansas

  • Kentucky Cancer Clinic

    Hazard, Kentucky

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland

  • Josephine Ford Cancer - Downriver

    Brownstown, Michigan

  • Henry Ford Medical Center- Fairlane

    Dearborn, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Henry Ford Hospital - West Bloomfield

    Detroit, Michigan

  • Regional Cancer Care Associates

    Cherry Hill, New Jersey

  • Study Supplies: Regional Cancer Care Associates

    Cherry Hill, New Jersey

  • Somerset Hematology Oncology Associates

    Somerville, New Jersey

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Associates In Oncology and Hematology

    Chattanooga, Tennessee

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas

  • Instituto Medico Especializado Alexander Fleming

    Buenos Aires, Argentina

  • Hospital Italiano de la Plata

    La Plata, Buenos Aires, Argentina

  • Hospital Privado de Cordoba

    Córdoba, Prov. de Cordoba, Argentina

  • Centro de Investigaciones Oncologicas

    Bahía Blanca, Provincia Buenos Aires, Argentina

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • C.H.R.ST. - R. Fabiola (N-D)

    Charleroi, Belgium

  • University Hospital Gent - Department of Hematology

    Ghent, Belgium

  • Centre Hospitalier de Jolimont - Lobbes

    La Louvière, Belgium

Showing 40 of 165 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.